STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] BRISTOL MYERS SQUIBB CO Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Bristol Myers Squibb announced the commencement of cash tender offers to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion, subject to the Pool 1 Maximum and Pool 2 Maximum.

The offers are being made only pursuant to the Company’s Offer to Purchase dated November 3, 2025, which sets forth the detailed terms and conditions. A related press release is furnished as Exhibit 99.1.

Positive
  • None.
Negative
  • None.

Insights

Debt management move: up to $7 billion in note tenders.

Bristol Myers Squibb launched cash tender offers for certain outstanding notes, capped in total at up to $7 billion. This is a liability management action that can reduce debt, interest expense, or extend maturities depending on which notes are accepted.

The structure includes Pool 1 and Pool 2 maximums, indicating caps across groupings of securities. Detailed pricing, series, and timing are set out in the Offer to Purchase dated November 3, 2025.

Actual impact depends on holder participation and final accepted amounts; the press release (Exhibit 99.1) and Offer to Purchase govern terms and mechanics.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K



CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025



BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)



Delaware
001-01136
22-0790350
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)

Route 206 & Province Line Road, Princeton, New Jersey 08543
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 252-4621



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.750% Notes due 2035
BMY35
New York Stock Exchange
Celgene Contingent Value Rights
CELG RT
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01
Other Events.
 
On November 3, 2025, Bristol-Myers Squibb Company (“Bristol Myers Squibb” or the “Company”) issued a press release announcing the commencement of cash tender offers (the “Offers”) to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion, subject to the Pool 1 Maximum and Pool 2 Maximum as described in the press release.
 
The Offers are subject to the terms and conditions described in the Company’s Offer to Purchase dated November 3, 2025 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a detailed description of the Offers.
 
A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
This Current Report on Form 8-K (including the exhibits attached hereto) is neither an offer to purchase nor a solicitation of an offer to sell any securities. The Offers are made only by, and pursuant to the terms of, the Offer to Purchase. The Offers do not constitute an offer to buy or the solicitation of an offer to sell the notes described herein in any jurisdiction in which such offer or solicitation is unlawful. The Offers are void in all jurisdictions where they are prohibited.
 
Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are included as part of this Current Report on Form 8-K:

Exhibit
No.
 
Description
     
99.1
 
Press release of Bristol-Myers Squibb Company dated November 3, 2025
     
104
 
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
     
Dated: November 3, 2025
By:
/s/ Amy Fallone
 
Name:
Amy Fallone
 
Title:
Senior Vice President and Corporate Secretary



Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

BMY Latest News

BMY Latest SEC Filings

BMY Stock Data

93.79B
2.03B
0.07%
82.82%
1.53%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON